meRfi®-GM
Breast Cancer / Mammacarcinoma (HER2+)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases
…
References (Sources)
- Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
- HER-2-positive metastatic breast cancer: trastuzumab and beyondReview
- Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
- Targeting HER2 heterogeneity in early-stage breast cancer
- Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer – a review of current evidence for and against the use of anti-HER2 treatment regimens